Therapeutic imatinib monitoring in patients with gastrointestinal stromal tumours.

被引：0
|
作者：
Spiliopoulou, Pavlina
Currie, Dawn
Haig, Caroline
Cowie, Fiona
White, Jeff D.
机构：
[1] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[2] Univ Glasgow, Inst Hlth & Wellbeing, Robertson Ctr Biostat, Glasgow, Lanark, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e22512
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e22512
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Resection of focally progressive gastrointestinal stromal tumours resistant to imatinib therapy
    Tse, G. H.
    Wong, E. H. C.
    O'Dwyer, P. J.
    SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND, 2012, 10 (06): : 309 - 313
  • [22] Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation
    Wilson, J
    Connock, M
    Song, F
    Yao, G
    Fry-Smith, A
    Raftery, J
    Peake, D
    HEALTH TECHNOLOGY ASSESSMENT, 2005, 9 (25) : IX - +
  • [23] Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib
    Gunhild Mechtersheimer
    Gerlinde Egerer
    Manfred Hensel
    Ralf J. Rieker
    Martin Libicher
    Thomas Lehnert
    Roland Penzel
    Virchows Archiv, 2004, 444 : 108 - 118
  • [24] Cost Effectiveness of Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumours
    Daniel M. Huse
    Margaret von Mehren
    Gregory Lenhart
    Heikki Joensuu
    Charles Blanke
    Weiwei Feng
    Stan Finkelstein
    George Demetri
    Clinical Drug Investigation, 2007, 27 : 85 - 93
  • [25] Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective
    Date, Ravindra S.
    Stylianides, Nicholas A.
    Pursnani, Kishore G.
    Ward, Jeremy B.
    Mughal, Muntzer M.
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2008, 6 (1)
  • [26] Is there a role for post-imatinib surgery in advanced gastrointestinal stromal tumours?
    Kuhlmann, K. F. D.
    Kerst, J. M.
    Cats, A.
    van Coevorden, F.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2009, 21 (03) : A3 - A3
  • [27] Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective
    Ravindra S Date
    Nicholas A Stylianides
    Kishore G Pursnani
    Jeremy B Ward
    Muntzer M Mughal
    World Journal of Surgical Oncology, 6
  • [28] Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib
    Mechtersheimer, G
    Egerer, G
    Hensel, M
    Rieker, RJ
    Libicher, M
    Lehnert, T
    Penzel, R
    VIRCHOWS ARCHIV, 2004, 444 (02) : 108 - 118
  • [29] Therapeutic drug monitoring and pharmacogenetics to tune imatinib exposure in gastrointestinal stromal tumor patients: hurdles and perspectives for clinical implementation
    Gagno, Sara
    Dalle Fratte, Chiara
    Posocco, Bianca
    Buonadonna, Angela
    Fumagalli, Arianna
    Guardascione, Michela
    Toffoli, Giuseppe
    Cecchin, Erika
    PHARMACOGENOMICS, 2023, 24 (18) : 895 - 900
  • [30] Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
    Gauden, Ruth
    Gauden, Stan
    CASE REPORTS IN ONCOLOGY, 2011, 4 (01): : 204 - 210
12345